公告显示，极客基因是一家以高通量组学数据调控细胞命运为特色的创新型细胞药物开发公司，主要从 事单细胞测序服务以及免疫细胞疗法开发业务，目前聚焦于开发长寿命肿瘤反应性 T 细胞药物用于治 疗中晚期实体肿瘤。 近日，博瑞医药发布公告称，拟向苏州极客基因科技有限公司增资5000万元，认缴新增注册资本43.71 万元，交易完成后将持有其12.8015%股权。 ...

Core Viewpoint - 康为世纪 plans to acquire the remaining 49% stake in its subsidiary, 上海昊为泰生物科技有限公司, for 17.885 million yuan, making it a wholly-owned subsidiary, which aims to enhance management control and improve overall profitability and competitiveness [1] Group 1: Acquisition Details - 康为世纪 currently holds a 51% stake in 昊为泰 and intends to purchase the remaining 49% from 上海天昊生物科技有限公司 [1] - The acquisition price is set at 17.885 million yuan [1] Group 2: Business Operations of 昊为泰 - 昊为泰's primary revenue comes from technology service income, including various testing services such as microbiome testing, multi-omics integration analysis, third-generation sequencing, single-cell sequencing, metabolomics, proteomics testing, and bioinformatics analysis [1] Group 3: Strategic Rationale - The acquisition aligns with 康为世纪's future strategic development plans and operational needs, aiming to strengthen control over 昊为泰 and enhance decision-making efficiency [1] - This move is expected to bolster the company's overall profitability and competitive edge in the market [1]